First Trust Nasdaq Pharmaceuticals ETF (FTXH) is a healthcare and biotech ETF. As of October 9, 2026, ETF Copilot scores FTXH 6.1 out of 10 — highest on Growth (8.5), lowest on Value (2.0). It trades at 28.3 times earnings, against its own median of 21.5. Its ten largest holdings are 55% of the fund.
What stands out in FTXH's data
US pharmaceutical and biotechnology companies ranked on income, asset returns and recent performance, weighted by cash flow.
Trades at a valuation in line with the pharma peer group — no discount, no premium for what it holds.
Trailing P/E multiple of 28.3x sits near the category median of 27.7x. Forward earnings are priced at 22.1x.
Offers focused exposure to US drug and biotech companies, selected by a rules-based ranking and weighted by cash flow.
Why did FTXH move this week? It rose 1.3% in the week to October 9, 2026 — Abbvie and Zoetis drove it
FTXH rose 1.3% in the week to October 9, 2026. The holdings that moved it most were Abbvie (+5.2%), Zoetis (+7.3%) and Eli Lilly (+3.2%); Jazz Pharmaceuticals (−7.3%) pushed the other way.
How is FTXH rated? ETF Copilot scores First Trust Nasdaq Pharmaceuticals ETF (FTXH) 6.1 out of 10
As of October 9, 2026, ETF Copilot scores First Trust Nasdaq Pharmaceuticals ETF (FTXH) 6.1 out of 10 overall.
ETF Copilot scores (0–10 scale, higher is better):
- Overall: 6.1 / 10
- Growth: 8.5 / 10
- Value: 2.0 / 10
- Risk: 7.2 / 10
- Quality: 6.7 / 10
- Return: 5.2 / 10
Is FTXH expensive right now? It trades at 28.3 times earnings, against its own median of 21.5
As of October 9, 2026, FTXH is more expensive than 93% of its own last 9 years.
Trailing 12 months, built from FTXH's holdings. How we calculate this →
What's inside FTXH?
What's inside FTXH: Size (Large 65%, Mid 32%, Small 3%); Geography (International 4%, US 97%); AI 0.3%.
What are FTXH's top holdings? The ten largest are 55% of the fund
Abbvie, Eli Lilly, Pfizer, Johnson & Johnson, Merck, Viatris, Biogen, Gilead Sciences, Zoetis and Amgen are FTXH's largest holdings, in that order.
More concentrated than 70% of Health & Biotech ETFs.
Half of FTXH's weight sits in its 9 largest positions, and once those weights are taken into account it behaves like 24 equally weighted holdings.
What is FTXH's expense ratio? 0.60% a year
As of October 9, 2026, FTXH charges 0.60% a year, yields 1.03% and holds $1.0B in assets across 50 positions.
| Measure | FTXH |
|---|---|
| Expense ratio | 0.60% |
| Dividend yield | 1.03% |
| Assets under management | $1.0B |
| Holdings | 50 |
Expense ratio, dividend yield and assets under management are reported by the fund and refreshed daily. Every other figure on this page is computed by ETF Copilot.
Cite this
ETF Copilot, “First Trust Nasdaq Pharmaceuticals ETF (FTXH) scores and holdings analysis”, as of October 9, 2026.
https://etf-copilot.com/etf/ftxh
ETF Copilot Pro unlocks FTXH's price and what each holding weighs.
Try Pro free →